Last Updated on May 4, 2024 by The Health Master
Revised Schedule M
The Indian pharmaceutical industry is poised for a significant transformation with the implementation of the Revised Schedule M.
This groundbreaking initiative promises to revolutionize the sector by not only boosting quality standards but also streamlining regulatory processes.
Simplifying Regulatory Landscape
A cornerstone of the Revised Schedule M is its focus on harmonizing international Good Manufacturing Practices (GMP) compliance and eliminating duplicative inspections.
This strategic move will significantly reduce administrative burdens for pharmaceutical manufacturers in India.
Previously, companies faced the challenge of undergoing multiple assessments by regulatory bodies from different countries.
The Revised Schedule M aims to streamline this process, fostering a more efficient and business-friendly environment.
“The emphasis on regulatory efficiency within the Revised Schedule M unlocks a multitude of benefits for both industry players and regulatory authorities,” explains a senior Central Drugs Standard Control Organisation (CDSCO) official.
“By harmonizing standards and reducing redundant inspections, the initiative not only enhances the ease of doing business but also cultivates an environment that fosters innovation and growth.”
Elevating Quality Standards
Beyond streamlining regulations, the Revised Schedule M places a strong emphasis on elevating pharmaceutical quality standards to match international benchmarks.
This is achieved through several key provisions, including:
- Retesting of Expired Active Pharmaceutical Ingredients (APIs): This ensures that even previously expired APIs can be utilized if they meet stringent quality and potency tests.
- Annual Product Quality Review (PQR): This mandates a comprehensive annual review of each pharmaceutical product, guaranteeing consistent quality throughout its lifecycle.
- Integration of Quality Risk Management (QRM) Practices: Proactive risk management helps identify and mitigate potential quality issues during the manufacturing process.
Industry Response
The Revised Schedule M has been met with positive industry response. Stakeholders recognize its potential to enhance competitiveness and bolster trust in Indian pharmaceutical products worldwide.
The implementation plan is designed for a smooth transition, with larger companies having six months to comply and medium and small-scale enterprises (MSMEs) being granted a year to adapt.
As India strives for excellence in pharmaceutical manufacturing and regulatory oversight, the Revised Schedule M paves the way for a brighter future.
This initiative fosters innovation through efficient regulations, ultimately safeguarding public health by ensuring the highest quality of pharmaceutical products.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
New Guidelines on Stability Studies for Medical Devices in India
USFDA Inspection: At Zydus Lifesciences with 10 observations
Pharma Industry to Achieve Global Standards with Schedule M Compliance
Isopropyl Alcohol Imports Get a Boost: Safeguard Measures Lifted in India
Lupin Receives EIR from USFDA for its Aurangabad Facility
Drug recall: Sapropterin Dihydrochloride recalled over potency concerns
Govt includes more Special Invitees into Committee for Pricing framework
USFDA Strengthens Collaboration with CDSCO
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
